Xiao, Ruo-Zhi <br/><br/>
Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.  [electronic resource] 

 -  Oncology reports  May 2013 
 - 1895-901 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1791-2431 
<br/><br/><label>Standard No.: </label>10.3892/or.2013.2331  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis--drug effects<br/>Butadienes--pharmacology<br/>Cell Line, Tumor<br/>Cell Proliferation<br/>Daunorubicin--administration & dosage<br/>Drug Synergism<br/>Extracellular Signal-Regulated MAP Kinases--antagonists & inhibitors<br/>Humans<br/>K562 Cells<br/>MAP Kinase Signaling System--drug effects<br/>Mitogen-Activated Protein Kinases--antagonists & inhibitors<br/>Niacinamide--administration & dosage<br/>Nitriles--pharmacology<br/>Phenylurea Compounds--administration & dosage<br/>Phosphorylation--drug effects<br/>Signal Transduction--drug effects<br/>Sorafenib<br/>U937 Cells<br/>Up-Regulation--drug effects